CANCERSCAPE Will Feature Insight on the Future of Value-Based Care, Drug Pricing Reform, Changes to Coverage and the Affordable Care Act (ACA), and Medicare from Political Experts and Industry Insiders

The new political environment is ushering in changes that could significantly impact cancer programs’ economic viability and patients’ access to care for years to come. Join leading experts in oncology care delivery who will provide valuable insight into the evolving healthcare policy landscape, value-based frameworks, drug pricing and more.

What: Association of Community Cancer Centers 43rd Annual Meeting, CANCERSCAPE

When: March 30-31, 2017

Where: Renaissance Washington, DC Downtown Hotel

Full agenda and meeting details are available here. To register, contact Lori Gardner at lgardner@accc-cancer.org. Meeting highlights include:

Keynote Session

The State of Healthcare Under the New Administration
Kavita Patel, MD, MS, FACP, The Brookings Institution
Dan Todd, JD, Todd Strategy
A 360-degree look at the healthcare landscape under the new administration from a Democrat and Republican perspective with insights on what oncology providers can expect in terms of reimbursement, alternative payment models, quality reporting, and more.

Featured Sessions

The State of Today’s Cancer Programs
Lindsay Conway, MSEd, The Advisory Board Company
An analysis of major market forces impacting oncology and the implications for strategic planning, financial forecasting, and budgeting; service line quality improvement initiatives; patient access; and more.

Drug Pricing Under the Trump Administration
Jessica Turgon, MBA, ECG Management Consultants
While President Trump has vowed to control drug costs under his administration, private payers and providers are acting now to address this through transparency mandates and outcomes-based drug pricing. Learn the latest federal policy options for tackling rising drug costs and ways cancer programs can proactively plan for these changes.

The ACA Under Trump: What’s Staying, What’s Going & What About Those State Exchanges?
Moderator: Kelly Brantley, MPH, Avalere Health
Alan Balch, PhD, Patient Advocate Foundation
Elizabeth Carpenter, Avalere Health
Clara Lambert, Cowell Family Cancer Center
The Trump Administration and Congress have named ACA repeal and replacement as one of their top priorities for 2017. Our expert panel will help translate what these changes might mean for cancer programs, and share practical strategies to help ensure that patients maintain adequate coverage during a time of potential upheaval.

Value-Based Frameworks—Everything Your Cancer Program Needs to Know
Stephen S. Grubbs, MD, American Society of Clinical Oncology
Ali McBride, PharmD, MS, BCPS, The University of Arizona Cancer Center
Robert W. Carlson, MD, National Comprehensive Cancer Network
Policymakers and providers will be expected to use value-based tools as part of broader efforts to reduce healthcare costs and improve care. Hear a review of oncology-specific value-based frameworks; their key components; possible benefits for cancer programs and implications for patients; implementation challenges; and a look ahead at how these tools might change practice patterns.

Alternative Payment Models in Radiation Oncology
Anne Hubbard, MBA, American Society for Radiation Oncology
Angela Kennedy, DC, MBA, American Society for Radiation Oncology
The American Society for Radiation Oncology (ASTRO) shares its development of a radiation oncology-specific alternative payment model.

Advancing High-Value Early Breast Cancer Care
Angie Meillier, RN, MS, CPPM, Abbott Northwestern Piper Breast Center
This cancer program implemented evidence-based quality improvement (QI) strategies, such as shared decision-making in treatment planning; use of short-course radiation planning; and reduction of re-excision rates to reduce costs of care and improve patient quality of life.

Translating Lessons Learned from the Oncology Care Model to Other APMs
Moderator: Wendalyn G. Andrews, Arizona Cancer Center
Nikolas Buescher, MHS, Lancaster General Hospital
Elizabeth Horenkamp, MD, Lancaster General Hospital
An administrator and physician champion share challenges and lessons learned through the Center for Medicaid and Medicare Innovation (CMMI) Oncology Care Model for practice redesign requirements, cultural buy-in, commercial provider partnerships, opportunities for improvement, and a look at what lies ahead.

340B—The Good, the Bad, and the Ugly
Bonnie Kirschenbaum, MS, FASHP, FCSHP, Consultant, Columnist
An update on the 340B Drug Pricing Program, including an analysis of last year’s proposed mega-guidance and what it means for hospitals, practices, and pharmaceutical companies. Plus, strategies to help providers manage multiple vendors, standardize processes, and maintain compliance.